<?xml version="1.0" encoding="UTF-8"?>
<p>In addition to AMR, unsustainable production and supply of existing impetigo antibiotics have been reported as a serious problem in remote settings, limiting the impetigo treatment options for children [
 <xref rid="B71-antibiotics-09-00909" ref-type="bibr">71</xref>]. Oral co-trimoxazole is available as a syrup suitable for young children under the brand names Bactrim and Septrin. In September 2018, Bactrim syrup was withdrawn from the market, leaving only a single brand of this antibiotic syrup available. As a result, the remaining manufacturer of the antibiotic has been unable to keep up with the demand. Septrin syrup has now been out of stock for over a year, and according to Australiaâ€™s Therapeutic Goods Administration Medicine Shortages Information Initiative, it is expected to be unavailable until 2021 [
 <xref rid="B72-antibiotics-09-00909" ref-type="bibr">72</xref>]. This, in turn, has left the health professionals in the area with the alternative option of crushing and giving the adult dose of co-trimoxazole tablets to children [
 <xref rid="B73-antibiotics-09-00909" ref-type="bibr">73</xref>]. This practice, not to mention the intolerable taste of the crushed tablets, is not recommended by antibiotic regulators as it does not meet the regulatory standards for administering a dose accurately to young children [
 <xref rid="B73-antibiotics-09-00909" ref-type="bibr">73</xref>].
</p>
